drugset / Trial / NCT06407635
A Study of Psilocybin for PTSD
Phase 1
Active not recruiting
20 enrolled
Johns Hopkins University
Steven & Alexandra Cohen Foundation · collabUsona Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.
Timeline
- Start
- 2024-06-07
- Primary completion
- 2026-03-09
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 40 mg | Oral |